Pharmaceutical composition for preventing or treating arteriosclerosis
Inventors
Cho, Yang Je • Jang, Jin Wook • Lim, Hyeong Joon
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9290542-B2
Publication Date
2016-03-22
Expiration Date
Abstract
The present invention provides a pharmaceutical composition for preventing or treating arteriosclerosis, comprising: a pharmaceutically effective amount of a protein comprising the amino acid sequence of SEQ ID NO: 1; and a pharmaceutically acceptable carrier. The composition of the present invention exhibits no toxicity in the liver or kidney and effectively reduces the formation of atherosclerotic plaques, thereby exhibiting efficacy in treating arteriosclerosis.
Core Innovation
The invention provides a pharmaceutical composition comprising a protein defined by the amino-acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable carrier. The protein is administered as a pharmaceutically effective amount for preventing or treating arteriosclerosis, preferably atherosclerosis, in a subject in need thereof.
The patent reports that administration of the SEQ ID NO:1 protein reduces aortic atherosclerotic plaque area in ApoE-KO mice fed a high-cholesterol diet. The disclosure also states that the administration does not induce detectable liver or kidney toxicity, including histopathology findings.
The disclosure further addresses formulation and administration route ranges and describes protein variants and modifications, including residue modifications and functionally equivalent sequence variants of the SEQ ID NO:1 protein.
Claims Coverage
The independent claims cover treatment of atherosclerosis by administering a SEQ ID NO:1 protein formulated with a pharmaceutically acceptable carrier, with an additional independent scope directed to patients having a defective apolipoprotein E gene. Across the independent claims, there are 2 main inventive feature groupings.
Administering SEQ ID NO:1 protein with pharmaceutically acceptable carrier
A method for treating atherosclerosis in a subject in need thereof, comprising administering a composition comprising a pharmaceutically effective amount of a protein consisting of the amino acid sequence of SEQ ID NO:1 and a pharmaceutically acceptable carrier.
Treating atherosclerosis in defective apolipoprotein E gene patients
The method wherein the atherosclerosis is one occurred in a patient having a defective apolipoprotein E gene.
Overall, the claim coverage focuses on using a pharmaceutically effective amount of the SEQ ID NO:1 sequence protein, formulated with a pharmaceutically acceptable carrier, to treat atherosclerosis, including an independent claim scope for patients having a defective apolipoprotein E gene.
Stated Advantages
Reduces aortic atherosclerotic plaque area in the ApoE-KO/high-cholesterol diet context.
Does not induce detectable liver or kidney toxicity, including histopathology reporting.
Documented Applications
Preventing or treating arteriosclerosis, preferably atherosclerosis, in a subject in need thereof, including experimental reduction of aortic atherosclerotic plaque area in ApoE-KO mice fed a high-cholesterol diet.
Interested in licensing this patent?